Hologic Announces Financial Results for Third Quarter of Fiscal 2022
July 28, 2022– Revenue of $1.003 Billion, GAAP Diluted EPS of $0.90, and Non-GAAP Diluted EPS of $0.95 All Significantly Ahead of Expectations –
– Global Organic Molecular Diagnostics ex-COVID-19 Revenue Grows Over 20% in Constant Currency –
– Company Again Increases Full-Year Revenue and EPS Guidance –
MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #3QFY22–Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 25, 2022.
“In our third quarter of fiscal 2022, Hologic delivered exceptionally strong growth in our base Diagnostics and Surgical franchises, powering financial results that meaningfully exceeded our guidance for both revenue and profitability,” said Steve MacMillan, the Company’s chairman, president and chief executive officer. “With strength in our base business, a natural hedge to COVID outbreaks, plus a fortified balance sheet and robust cash flow, we have high confidence in our business. In addition, with a presence advocating for women’s health at this year’s World Economic Forum Annual Meeting, Hologic continues to drive our message on the global stage to impact more women around the world.”
Recent Highlights
- Revenue of $1.003 billion decreased (14.2%) for the quarter, or (12.2%) in constant currency, primarily driven by lower international sales of COVID-19 assays and supply chain challenges related to semiconductor chips in our Breast Health business compared to the prior year period. Revenue, however, was significantly higher than the Company’s guidance of $875 to $915 million provided last quarter.
- Excluding revenue from COVID-19, organic revenue declined (1.4%) on a constant currency basis primarily due to persistent semiconductor chip shortages impacting the Breast Health business.
- Global diagnostics revenue decreased (15.8%), or (13.6%) in constant currency, primarily driven by lower international sales of COVID-19 assays compared to the prior year period. Excluding COVID-19 revenues, global diagnostics revenue grew 15.0% on an organic, constant currency basis. Similarly, global molecular diagnostics revenue declined (18.9%), or (16.8%) in constant currency, yet grew 22.4% on an organic, constant currency basis excluding COVID-19 revenues.
- Global revenue for the Company’s Breast Health business declined (19.0%), or (17.5%) in constant currency, as expected, primarily due to semiconductor chip shortages. However, gantry demand remains strong.
- Global revenue for the Company’s Surgical business grew 8.0%, or 9.7% in constant currency, primarily driven by MyoSure, Fluent Fluid Management System sales, and Bolder.
- Cash flow from operations remained very strong in the third quarter at $330.6 million.
-
Assay approvals in molecular diagnostics:
- Received FDA approval for our Aptima CMV Quant assay to quantify the viral load of cytomegalovirus (CMV) in patients who have had solid organ or stem cell transplants.
- Received European CE mark for our Panther Fusion EBV Quant assay and Panther Fusion BKV Quant assay, to further expand pathogen monitoring menu on the Panther Fusion system.
- Received European CE mark for our Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Novodiag RESP-4 molecular diagnostic test. Both assays detect and differentiate four of the most prevalent respiratory viruses that can present with similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (Flu A), influenza B (Flu B) and respiratory syncytial virus (RSV).
Key financial results for the fiscal third quarter are shown in the table below.
|
|
GAAP |
|
Non-GAAP |
||||
|
|
Q3’22 |
Q3’21 |
Change Increase (Decrease) |
Q3’22 |
Q3’21 |
Change Increase (Decrease) |
|
|
Revenues |
$1,002.7 |
$1,168.3 |
(14.2%) |
|
$1,002.7 |
$1,168.3 |
(14.2%) |
|
Gross Margin |
54.8% |
60.1% |
(530 bps) |
|
63.3% |
66.1% |
(280 bps) |
|
Operating Expenses |
$285.9 |
$343.0 |
(16.6%) |
|
$311.2 |
$310.1 |
0.4% |
|
Operating Margin |
26.3% |
30.7% |
(440 bps) |
|
32.3% |
39.5% |
(720 bps) |
|
Net Margin |
22.8% |
22.9% |
(10 bps) |
|
24.1% |
29.5% |
(540 bps) |
|
Diluted EPS |
$0.90 |
$1.04 |
(13.5%) |
$0.95 |
$1.33 |
(28.6%) |
|
Throughout this press release, all dollar figures are in millions, except EPS, unless otherwise noted. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. Our fiscal third quarter organic revenue results exclude the divested Blood Screening business, as well as the acquired Mobidiag and Bolder businesses. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition.
Revenue Detail
|
|
|
|
Increase (Decrease) |
||||||||||
|
$ in millions |
Q3’22 |
Q3’21 |
Global Reported Change |
Global Constant Currency Change |
U.S. Reported Change |
International Reported Change |
International Constant Currency Change |
||||||
|
Diagnostics |
|
|
|
|
|
|
|
||||||
|
Cytology and Perinatal |
$115.9 |
|
$115.9 |
|
0.0% |
|
3.5% |
|
0.6% |
|
(1.0%) |
|
8.5% |
|
Molecular Diagnostics |
$435.3 |
|
$536.4 |
|
(18.9%) |
|
(16.8%) |
|
12.6% |
|
(50.7%) |
|
(46.7%) |
|
Blood Screening |
$8.9 |
|
$13.2 |
|
(32.6%) |
|
(32.6%) |
|
(32.6%) |
|
N/A |
|
N/A |
|
Total Diagnostics |
$560.1 |
|
$665.5 |
|
(15.8%) |
|
(13.6%) |
|
8.4% |
|
(44.0%) |
|
(39.2%) |
|
Organic Diagnostics ex. COVID-19 |
$333.5 |
|
$296.6 |
|
12.4% |
|
15.0% |
|
14.5% |
|
7.0% |
|
16.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Breast Health |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Breast Imaging |
$212.2 |
|
$280.3 |
|
(24.3%) |
|
(22.9%) |
|
(24.2%) |
|
(24.5%) |
|
(18.1%) |
|
Interventional Breast Solutions |
$70.6 |
|
$68.7 |
|
2.8% |
|
4.2% |
|
3.6% |
|
(0.4%) |
|
6.6% |
|
Total Breast Health |
$282.8 |
|
$349.0 |
|
(19.0%) |
|
(17.5%) |
|
(18.6%) |
|
(20.1%) |
|
(13.5%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GYN Surgical |
$138.1 |
|
$127.9 |
|
8.0% |
|
9.7% |
|
8.0% |
|
7.8% |
|
16.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Skeletal Health |
$21.7 |
|
$25.9 |
|
(16.1%) |
|
(13.6%) |
|
(18.2%) |
|
(12.8%) |
|
(6.6%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
$1,002.7 |
|
$1,168.3 |
|
(14.2%) |
|
(12.2%) |
|
(2.0%) |
|
(35.9%) |
|
(30.5%) |
|
Organic (definition above) |
$985.8 |
|
$1,153.9 |
|
(14.6%) |
|
(12.6%) |
|
(1.8%) |
|
(37.1%) |
|
(31.6%) |
|
Organic ex. COVID-19 |
$773.0 |
|
$799.4 |
|
(3.3%) |
|
(1.4%) |
|
(2.8%) |
|
(5.0%) |
|
3.1% |
Other Financial Highlights
- U.S. revenue of $734.6 million decreased (2.0%). International revenue of $268.1 million decreased (35.9%), or (30.5%) in constant currency.
- GAAP gross margin of 54.8% decreased (530) basis points. Non-GAAP gross margin of 63.3% decreased (280) basis points. The decrease in gross margin was primarily due to a decline in international COVID-19 assay sales compared to the prior year period and supply chain challenges related to semiconductor chips in our Breast Health business.
- GAAP operating margin of 26.3% decreased (440) basis points. Non-GAAP operating margin of 32.3% decreased (720) basis points. The decrease in operating margin was primarily due to a decline in international COVID-19 assay sales compared to the prior year period and supply chain challenges related to semiconductor chips in our Breast Health business.
- GAAP net income attributable to Hologic of $228.4 million decreased (14.9%). Non-GAAP net income attributable to Hologic of $241.5 million decreased (30.0%). Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) was $348.3 million, a decrease of (27.9%).
- COVID-19 revenues, which consist of COVID-19 assay revenue of $172.9 million, and other COVID-19 related revenue and revenue from discontinued products of $39.9 million, decreased (40.0%), or (38.0%) in constant currency.
- Total principal debt outstanding at the end of the third quarter was $2.85 billion. The Company ended the quarter with cash and equivalents of $2.4 billion, and a net leverage ratio (net debt over adjusted EBITDA) of 0.2.
- On a trailing 12 months basis, adjusted Return on Invested Capital (ROIC) of 25.3% decreased (940) basis points compared to the prior year period.
Financial Guidance for the Fourth Quarter and Full-Year Fiscal 2022
“Our fiscal third quarter 2022 was financially very strong, with performance exceeding revenue and EPS expectations,” said Karleen Oberton, Hologic’s chief financial officer. “In our fiscal fourth quarter, we expect continued strength in our base Diagnostics and Surgical businesses to counterbalance supply chain headwinds in our Breast Health business.”
Hologic’s financial guidance for the fourth quarter and full year 2022 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 21.0%, and diluted shares outstanding of 254 million for the full year. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2022 as in fiscal 2021. Organic revenue guidance is in constant currency and excludes the divested Blood Screening business. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition. Therefore, in fiscal 2022, Biotheranostics and Diagenode are part of organic revenue in the fiscal third quarter, Mobidiag is part of organic revenue in the fiscal fourth quarter, and Bolder is excluded from organic revenue for the full year.
|
|
|
||||
|
|
Current Guidance |
Previous Guidance |
|||
|
|
Guidance $ |
Reported % Increase (Decrease) |
Constant Currency % Increase (Decrease) |
Organic % Increase (Decrease) |
Guidance $ |
|
Fiscal 2022 |
|
|
|
|
|
|
Revenue |
$4,750 – $4,780 |
(15.7%) to (15.1%) |
(14.4%) to (13.8%) |
(15.4%) to (14.9%) |
$4,600 – $4,700 |
|
GAAP EPS |
$4.98 – $5.03 |
(30.9%) to (30.2%) |
|
|
$4.36 – $4.56 |
|
Non-GAAP EPS |
$5.79 – $5.84 |
(31.2%) to (30.6%) |
|
|
$5.45 – $5.65 |
|
|
|
|
|
|
|
|
Q4 2022 |
|
|
|
|
|
|
Revenue |
$840 – $870 |
(36.2%) to (33.9%) |
(34.5%) to (32.2%) |
(34.4%) to (32.1%) |
|
|
GAAP EPS |
$0.33 – $0.38 |
(74.2%) to (70.3%) |
|
|
|
|
Non-GAAP EPS |
$0.60 – $0.65 |
(62.7%) to (59.6%) |
|
|
|
Use of Non-GAAP Financial Measures
The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID-19, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; and adjusted EBITDA. Organic revenue excludes the divested Blood Screening business, as well as the acquired Mobidiag, and Bolder businesses as noted above. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition. Organic revenue excluding COVID-19 is organic revenue less COVID assay revenue, COVID related sales of instruments, collection kits and ancillaries, as well as license revenue, and revenues from discontinued products. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill, intangible assets and equipment; (ii) adjustments to record contingent consideration at fair value; (iii) additional expenses resulting from the purchase accounting adjustment to record inventory at fair value; (iv) restructuring and divestiture charges and facility closure and consolidation charges, including accelerated depreciation, and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services) and separate divested businesses from existing operations; (v) expenses related to the divested Cynosure business incurred subsequent to the disposition date primarily related to indemnification provisions for legal and tax matters; (vi) transaction related expenses for divestitures and acquisitions; (vii) third-party expenses incurred related to implementing the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products; (viii) debt extinguishment losses and related transaction costs; (ix) the unrealized (gains) losses on the mark-to-market of foreign currency contracts for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the one-time discrete impacts related to internal restructurings and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company’s core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income.
These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others.
The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Hologic’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic’s business.
Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.
Conference Call and Webcast
Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the third quarter of fiscal 2022. Interested participants may listen to the call by dialing 800-289-0720 (in the U.S. and Canada) or +1 323-701-0160 (for international callers) and referencing access code 6025981. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. A replay will be available approximately two hours after the call ends through Friday, August 26, 2022. The replay numbers are 888-203-1112 (U.S.) or +1 719-457-0820 (international), access code 6025981, PIN 3270. The Company will also provide a live webcast of the call at investors.hologic.com.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the Company’s outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
Risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the severity and duration of the COVID-19 pandemic and its impact on the U.S. healthcare system, the U.S. economy and worldwide economy; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic; disruption of supply chains, including the availability of critical raw materials and components, including semiconductor chips, or more commonly referred to as chips, as well as cost inflation in materials, packaging and transportation; manufacturing risks, including the Company’s reliance on a single or limited source of supply for key components, the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; continued demand for the Company’s COVID-19 TMA assay; the Company’s ability to manufacture, on a scale necessary to meet demand, its COVID-19 TMA assay as well as the Panther systems on which the assay runs; U.S., European and general worldwide economic conditions, including recession concerns, trade relations, and related uncertainties; the Company’s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the Company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company’s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company’s international activities and businesses; the early stage of market development for certain of the Company’s products; the Company’s leverage risks, including the Company’s obligation to meet payment obligations and financial covenants associated with its debt; cybersecurity risks; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.
The risks included above are not exhaustive. Other factors that could adversely affect the Company’s business and prospects are described in the filings made by the Company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
SOURCE: Hologic, Inc.
|
HOLOGIC, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In millions, except number of shares, which are reflected in thousands, and per share data) |
|||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
June 25, 2022 |
|
June 26, 2021 |
|
June 25, 2022 |
|
June 26, 2021 |
||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
Revenues: |
|
|
|
|
|
|
|
||||||||
|
Product |
$ |
837.1 |
|
|
$ |
995.2 |
|
|
$ |
3,408.7 |
|
|
$ |
3,829.4 |
|
|
Service and other |
|
165.6 |
|
|
|
173.1 |
|
|
|
500.9 |
|
|
|
486.3 |
|
|
Total revenues |
|
1,002.7 |
|
|
|
1,168.3 |
|
|
|
3,909.6 |
|
|
|
4,315.7 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Cost of revenues: |
|
|
|
|
|
|
|
||||||||
|
Product |
|
266.3 |
|
|
|
303.9 |
|
|
|
907.0 |
|
|
|
889.1 |
|
|
Amortization of acquired intangible assets |
|
75.9 |
|
|
|
68.1 |
|
|
|
223.1 |
|
|
|
194.2 |
|
|
Impairment of intangible assets |
|
9.2 |
|
|
|
— |
|
|
|
9.2 |
|
|
|
— |
|
|
Service and other |
|
101.5 |
|
|
|
94.7 |
|
|
|
287.6 |
|
|
|
264.7 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Gross profit |
|
549.8 |
|
|
|
701.6 |
|
|
|
2,482.7 |
|
|
|
2,967.7 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
|
Research and development |
|
65.1 |
|
|
|
69.0 |
|
|
|
207.4 |
|
|
|
199.8 |
|
|
Selling and marketing |
|
152.3 |
|
|
|
142.7 |
|
|
|
471.0 |
|
|
|
402.2 |
|
|
General and administrative |
|
91.9 |
|
|
|
117.3 |
|
|
|
310.5 |
|
|
|
297.7 |
|
|
Amortization of acquired intangible assets |
|
11.2 |
|
|
|
10.4 |
|
|
|
33.2 |
|
|
|
30.7 |
|
|
Contingent consideration fair value adjustments |
|
(35.4 |
) |
|
|
— |
|
|
|
(39.5 |
) |
|
|
(10.1 |
) |
|
Restructuring and divestiture charges |
|
0.8 |
|
|
|
3.6 |
|
|
|
0.8 |
|
|
|
6.6 |
|
|
Total operating expenses |
|
285.9 |
|
|
|
343.0 |
|
|
|
983.4 |
|
|
|
926.9 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Income from operations |
|
263.9 |
|
|
|
358.6 |
|
|
|
1,499.3 |
|
|
|
2,040.8 |
|
|
Interest income |
|
2.4 |
|
|
|
0.4 |
|
|
|
3.6 |
|
|
|
1.1 |
|
|
Interest expense |
|
(22.7 |
) |
|
|
(21.6 |
) |
|
|
(71.0 |
) |
|
|
(70.9 |
) |
|
Debt extinguishment loss |
|
— |
|
|
|
— |
|
|
|
(0.7 |
) |
|
|
(21.6 |
) |
|
Other income, net |
|
4.8 |
|
|
|
0.1 |
|
|
|
13.6 |
|
|
|
1.1 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Income before income taxes |
|
248.4 |
|
|
|
337.5 |
|
|
|
1,444.8 |
|
|
|
1,950.5 |
|
|
Provision for income taxes |
|
20.0 |
|
|
|
69.4 |
|
|
|
261.5 |
|
|
|
409.6 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income |
$ |
228.4 |
|
|
$ |
268.1 |
|
|
$ |
1,183.3 |
|
|
$ |
1,540.9 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net loss attributable to noncontrolling interest |
|
— |
|
|
|
(0.3 |
) |
|
|
— |
|
|
|
(1.8 |
) |
|
Net income attributable to Hologic |
$ |
228.4 |
|
|
$ |
268.4 |
|
|
$ |
1,183.3 |
|
|
$ |
1,542.7 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income per common share attributable to Hologic: |
|
|
|
|
|
|
|
||||||||
|
Basic |
$ |
0.91 |
|
|
$ |
1.05 |
|
|
$ |
4.70 |
|
|
$ |
5.98 |
|
|
Diluted |
$ |
0.90 |
|
|
$ |
1.04 |
|
|
$ |
4.65 |
|
|
$ |
5.93 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Weighted average number of shares outstanding: |
|
|
|
|
|
|
|
||||||||
|
Basic |
|
250,756 |
|
|
|
256,230 |
|
|
|
251,943 |
|
|
|
257,769 |
|
|
Diluted |
|
253,093 |
|
|
|
258,581 |
|
|
|
254,273 |
|
|
|
260,371 |
|
| HOLOGIC, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In millions) |
|||||||
|
|
June 25, 2022 |
|
September 25, 2021 |
||||
|
ASSETS |
|
|
|
||||
|
|
|
|
|
||||
|
Current assets: |
|
|
|
||||
|
Cash and cash equivalents |
$ |
2,375.3 |
|
$ |
1,170.3 |
||
|
Accounts receivable, net |
|
702.9 |
|
|
|
942.7 |
|
|
Inventories |
|
581.2 |
|
|
|
501.2 |
|
|
Other current assets |
|
249.6 |
|
|
|
554.5 |
|
|
Total current assets |
|
3,909.0 |
|
|
|
3,168.7 |
|
|
|
|
|
|
||||
|
Property, plant and equipment, net |
|
490.1 |
|
|
|
564.7 |
|
|
Goodwill and intangible assets, net |
|
4,722.4 |
|
|
|
4,940.8 |
|
|
Other assets |
|
235.9 |
|
|
|
245.7 |
|
|
Total assets |
$ |
9,357.4 |
|
|
$ |
8,919.9 |
|
|
|
|
|
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
||||
|
|
|
|
|
||||
|
Current liabilities: |
|
|
|
||||
|
Current portion of long-term debt |
$ |
7.5 |
|
|
$ |
313.0 |
|
|
Accounts payable and accrued liabilities |
|
793.8 |
|
|
|
815.8 |
|
|
Deferred revenue |
|
199.6 |
|
|
|
198.0 |
|
|
Total current liabilities |
|
1,000.9 |
|
|
|
1,326.8 |
|
|
|
|
|
|
||||
|
Long-term debt, net of current portion |
|
2,814.6 |
|
|
|
2,712.2 |
|
|
Deferred income taxes |
|
208.3 |
|
|
|
250.5 |
|
|
Other long-term liabilities |
|
335.7 |
|
|
|
411.8 |
|
|
Total stockholders’ equity |
|
4,997.9 |
|
|
|
4,218.6 |
|
|
Total liabilities and stockholders’ equity |
$ |
9,357.4 |
|
|
$ |
8,919.9 |
|
Contacts
Ryan Simon
Vice President, Investor Relations
[email protected]
(858) 410-8514
Francis Pruell
Director, Investor Relations
[email protected]
(508) 263-8628